01—Abstract
Summary
Summary of the 10-Q filed May 2, 2025. Cited figures are marked; the original filing is the authoritative source.
Stryker Corporation (SYK) reported its first-quarter 2025 results, showcasing robust top-line growth driven by strategic acquisitions and organic expansion.
Net sales increased by 11.9% year-over-year to $5.87 billiona, with constant currency growth of 12.8%. This growth was propelled by a 13.4% increase in the MedSurg and Neurotechnology segment and a 9.7% rise in the Orthopaedics segment. The company's profitability faced pressure from increased selling, general, and administrative expenses, largely due to acquisition-related costs, including a significant charge for Inari employee stock awards.
As a result, net earnings decreased by 17.0% to $654 million, and diluted EPS fell to $1.69b from $2.05 in the prior year. However, adjusted EBITDA margin showed a healthier trend, indicating underlying operational strength. Financially, Stryker bolstered its liquidity through significant debt issuances, raising $2.98 billion in long-term debt.
The company ended the quarter with a strong cash position, though it was reduced by substantial investing activities, primarily the Inari acquisition. The strategic acquisition of Inari, a leader in minimally invasive products for venous thromboembolism, is expected to enhance Stryker's Vascular business and drive future growth.
02—Key points
Key Highlights
- Net sales grew 11.9% to $5.87 billion, driven by 13.4% in MedSurg/Neurotechnology and 9.7% in Orthopaedics.
- Acquisition of Inari Medical for $4.75 billion significantly boosted the Vascular business and contributed to overall sales growth.
- Net earnings declined 17.0% to $654 million ($1.69/share) due to increased SG&A expenses, particularly acquisition-related costs.
- Selling, General, and Administrative (SG&A) expenses rose 25.2% primarily due to a $139 million charge for Inari employee stock awards and other integration costs.
- The company raised $2.98 billion in new long-term debt, enhancing its liquidity position.
- Stryker is divesting its US Spinal Implants business, completing the sale in April 2025.
- Operating income margin decreased to 14.3% from 18.5% in the prior year, impacted by higher operating expenses.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2025, Stryker Corp kept $0.11.
- Revenue$5.87B100.0%
- Cost of revenue−$2.12B36.2%
- Gross profit$3.74B63.8%
- Operating costs−$2.91B49.6%
- Operating income$837.0M14.3%
- Interest, other & tax−$183.0M3.1%
- Net income$654.0M11.1%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed May 2, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $5.87B$5.24B | +11.9% |
| Cost of Revenue | $2.12B$1.91B | +11.1% |
| Gross Profit | $3.74B$3.33B | +12.3% |
| R&D Expenses | $405.00M$368.00M | +10.1% |
| SG&A Expenses | $2.30B$1.84B | +25.2% |
| Operating Expenses | $2.91B$2.36B | +23.1% |
| Operating Income | $837.00M$972.00M | −13.9% |
| Interest Expense | $132.00M— | — |
| Net Income | $654.00M$788.00M | −17.0% |
| EPS (Basic) | $1.71$2.07 | −17.4% |
| EPS (Diluted) | $1.69$2.05 | −17.6% |
| Shares Outstanding (Basic) | 381.70M380.40M | +0.3% |
| Shares Outstanding (Diluted) | 386.40M385.10M | +0.3% |
05—Questions
Frequently Asked Questions
What was the primary driver of Stryker's top-line growth in Q1 2025?
Stryker's top-line growth was driven by a combination of organic growth across its MedSurg and Neurotechnology and Orthopaedics segments, and the significant contribution from its recent acquisition of Inari Medical. The Inari acquisition particularly bolstered the Vascular business within the MedSurg and Neurotechnology segment.
Why did net earnings and EPS decrease despite strong sales growth?
Net earnings and diluted EPS decreased primarily due to a substantial increase in Selling, General, and Administrative (SG&A) expenses. This increase was largely attributable to acquisition-related costs, including a one-time charge of $139 million for Inari employee stock awards that vested upon acquisition, as well as other integration costs and ongoing investments to support growth.
How did Stryker fund the Inari acquisition, and what is its current liquidity position?
The Inari acquisition was funded through a combination of cash flows and significant debt issuance. In February 2025, Stryker issued approximately $2.98 billion in senior unsecured notes. The company ended the quarter with $2.32 billion in cash and cash equivalents, and a healthy current ratio, indicating strong liquidity to support operations and ongoing strategic initiatives.
What is the significance of the Inari acquisition for Stryker?
The acquisition of Inari Medical is a strategic move to expand Stryker's presence in the minimally invasive treatment of venous thromboembolism. Inari's product portfolio complements Stryker's existing Vascular business within the MedSurg and Neurotechnology segment, offering opportunities for cross-selling, innovation, and further market penetration in a growing area of medical technology.
06—Continue